REFERENCES
1. Stirland LE, González-Saavedra L, Mullin DS, Ritchie CW, Muniz-Terrera G, Russ TC. Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice. BMJ (Clinical research ed). 2020;368:m160.
2. Soley-Bori M, Ashworth M, Bisquera A, et al. Impact of multimorbidity on healthcare costs and utilisation: a systematic review of the UK literature. The British journal of general practice : the journal of the Royal College of General Practitioners. 2020.
3. Mair FS, Foster HM, Nicholl BI. Multimorbidity and the COVID-19 pandemic - An urgent call to action. J Comorb.2020;10:2235042x20961676.
4. Maddaloni E, D’Onofrio L, Alessandri F, et al. Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovascular diabetology. 2020;19(1):164.
5. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis.PLoS medicine. 2020;17(9):e1003321.
6. Wang Y, Wang Z, Tse G, et al. Cardiac arrhythmias in patients with COVID-19. J Arrhythm. 2020;36(5):827-836.
7. Stone E, Kiat H, McLachlan CS. Atrial fibrillation in COVID-19: A review of possible mechanisms. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2020;34(9):11347-11354.
8. Proietti M, Marzona I, Vannini T, et al. Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. Mayo Clinic proceedings. 2019;94(12):2427-2436.
9. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. [updated March 2011] http://handbook.cochrane.org.
10. Hermans ANL, van der Velden RMJ, Gawalko M, et al. On-demand mobile health infrastructures to allow comprehensive remote atrial fibrillation and risk factor management through teleconsultation. Clinical cardiology. 2020;43(11):1232-1239.
11. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European heart journal. 2020.
12. Fauchier L, Bodin A, Bisson A, et al. Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis. Journal of clinical medicine. 2020;9(4).
13. Chao TF, Lip GYH, Lin YJ, et al. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors.Thrombosis and haemostasis. 2018;118(4):768-777.
14. Yoon M, Yang PS, Jang E, et al. Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. Thrombosis and haemostasis. 2018;118(7):1296-1304.
15. Guo Y, Guo J, Shi X, et al. Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. European journal of internal medicine. 2020;82:105-111.
16. Guo Y, Lane DA, Wang L, et al. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2020;75(13):1523-1534.
17. Guo Y, Lane DA, Chen Y, Lip GYH, m AFAIITi. Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. The American journal of medicine.2020;133(10):1195-1202 e1192.